EBR/NYXH (EBR/NYXH)

Euronext Brussels: EBR/NYXH · EUR

€0.85

+0.02 (+2.2%)· Recorded snapshot

Market cap	85.4M
Revenue (ttm)	21.7M
Net income (ttm)	-96M
EPS (ttm)	-€2.16
Shares out	100.1M
Volume	224,497
Beta	1.00

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 21.7M
Net income (ttm): -96M
EPS (ttm): -€2.16
Market cap: 85.4M

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-29 13:30 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-122.7

P25 n/aP50 n/aP75 n/a

ROIC-44

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All EBR/NYXH indicators

Market & fundamental data

Available fields

180

Groups with data

Currency

EUR

Showing 180 of 180 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	EUR
Country	Belgium
Country code	BE
Earnings date	2026-11-05
Employees	154
Employees change	-30
Employees growth	-16.29%
Enterprise value	EUR 47.6M
Exchange	Euronext Brussels
Financial currency	EUR
Financial report date	2026-06-30
First seen	2026-05-10
Fiscal year end	December
Founded	2009
Industry	Medical Devices
Is primary listing	Yes
ISIN number	BE0974358906
Last earnings date	2026-08-05
Last refreshed	2026-10-29
Market cap	EUR 85.4M
Next earnings date	2026-11-05
Price	EUR 0.85
Price currency	EUR
Sector	Healthcare
SIC code	3841
Stock price date	2026-10-28
Symbol	ebr/NYXH
Website	https://www.nyxoah.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-253.17%
EV/Sales	2.2x
FCF / EV yield	-155.38%
FCF yield	-86.58%
P/B ratio	1.03x
P/S ratio	3.94x
Price / tangible book value	1.03x
Sector forward P/E	22.94x
Sector P/E	29.62x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross margin	60.19%
Operating margin	-387.96%
Pretax margin	-436.37%
Profit per employee	EUR -623,403
Revenue per employee	EUR 140,669
ROA	-36.87%
ROA (5Y)	-21.78%
ROCE	-69.34%
ROE	-122.68%
ROE (5Y)	-50.46%
ROIC	-43.97%
SBC / revenue	20.63%
Tax / revenue	6.8%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Gross profit growth	304.94%
Gross profit growth (Q)	439.29%
Gross profit growth 3Y	89.5%
Gross profit growth 5Y	319.81%
Revenue growth	339.15%
Revenue growth (Q)	472.76%
Revenue growth (QoQ)	20.45%
Revenue growth 3Y	92.5%
Revenue growth 5Y	119.62%

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	EUR -2.1M
Depreciation and amortization	EUR 1.3M
EBIT	EUR -84M
EBITDA	EUR -82.7M
EPS	EUR -2.16
FCF per share	EUR -0.74
Financing cash flow	EUR 128.3M
Free cash flow	EUR -73.9M
Free cash flow minus SBC	EUR -78.4M
Gross profit	EUR 13M
Income taxes	EUR 1.5M
Investing cash flow	EUR -16.2M
Net borrowing	EUR 34.9M
Net cash flow	EUR 41.4M
Net income	EUR -96M
Operating cash flow minus SBC	EUR -76.3M
Operating income	EUR -84M
Revenue	EUR 21.7M
Stock-based compensation	EUR 4.5M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	-2.8
Book value per share	EUR 0.83
Debt / equity	0.72
Interest coverage	-24.59
Long-term assets	EUR 55.8M
Long-term liabilities	EUR 38.1M
Net cash (debt)	EUR 37.8M
Net cash / market cap	44.28%
Net cash growth	83.62%
Net debt / equity	-0.45
Piotroski F-Score	2
Property, plant and equipment	EUR 5.9M
Shareholders' equity	EUR 83.1M
Tangible book value	EUR 82.8M
Tangible book value per share	EUR 0.83
Total assets	EUR 168.5M
Total cash	EUR 97.8M
Total debt	EUR 60M
Total liabilities	EUR 85.4M
WACC	7.59%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.15
Current assets	EUR 112.7M
Current liabilities	EUR 47.3M
Current ratio	2.38
Inventory turnover	1.91
Net working capital	EUR -8.7M
Quick ratio	2.28
Working capital	EUR 65.4M
Working capital turnover	0.44

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-21.45%
Shareholder yield	-21.45%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	EUR 1.71
1D price change	2.16%
1M price change	-33.36%
1M total return	-33.36%
1W price change	0.12%
1W total return	0.12%
1Y price change	-81.46%
1Y return CAGR	-81.48%
1Y total return	-81.46%
20-day SMA	EUR 1.04
200-day SMA	EUR 2.17
3M price change	-31.87%
3M total return	-31.87%
3Y price change	-85.44%
3Y return CAGR	-47.39%
3Y total return	-85.44%
50-day SMA	EUR 1.23
50-day SMA vs 200-day SMA	50under200
52-week high	EUR 5.14
52-week high date	2025-11-13
52-week low	EUR 0.70
52-week low date	2026-10-22
5Y price change	-95.84%
5Y return CAGR	-47.06%
5Y total return	-95.84%
6M price change	-67.19%
6M total return	-67.19%
All-time high	EUR 30.00
All-time high date	2021-07-13
All-time low	EUR 0.70
All-time low date	2026-10-22
Average true range (ATR)	EUR 0.09
Average volume	272.3K
Beta (1Y)	1.55
Beta (2Y)	0.99
Beta (5Y)	1
Change from 52-week high	-83.4%
Change from 52-week low	22.38%
Change from all-time high	-97.16%
Change from all-time low	22.38%
Change from open	-0.47%
Day's gap	2.63%
Dollar volume	EUR 191,496
High price	EUR 0.90
Low price	EUR 0.84
Monthly RSI	30.39
Open price	EUR 0.86
Position in 52-week range	20.63%
Previous close	EUR 0.84
Price vs 150-day SMA	-50.23%
Price vs 20-day SMA	-17.66%
Price vs 200-day SMA	-60.71%
Price vs 50-day SMA	-30.59%
Relative volume	0.82
RSI	34.98
Sharpe ratio	-1.75
Sharpe ratio (3Y)	-0.33
Sharpe ratio (5Y)	-0.56
Sortino ratio	-2.06
Sortino ratio (3Y)	-0.39
Sortino ratio (5Y)	-0.71
Volume	224.5K
Weekly RSI	26.58
YTD price change	-79.12%
YTD total return	-79.12%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	50.9M
Shares change (QoQ)	31.87%
Shares change (YoY)	21.45%
Shares held by insiders	26.26%
Shares held by institutions	12.62%
Shares outstanding	100.1M

Deeper analysis on EBR/NYXH

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this EBR/NYXH report

Is a complete EBR/NYXH research report available?

No complete published report is available for ebr/NYXH (EBR/NYXH) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

EBR/NYXH (EBR/NYXH)

Price

Financial snapshot

Fair-value bridge

Latest news · EBR/NYXH

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All EBR/NYXH indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on EBR/NYXH

Frequently asked questions